http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1964563-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24b4aee11752e7c69e485a21d0282e12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2006-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0671a01d9f499272a46268ee123391d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2e7c165e938105155c220d30c58c78e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbc51404001260d6d6f1f485624bef7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27c09e31a2ca0b5280e3a0f31577fbaa |
| publicationDate | 2008-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1964563-A1 |
| titleOfInvention | Pharmaceutical compositions containing calcium antagonist substances combined with platelet aggregation inhibiting agents for use in systemic arterial hypertension and for the prevention of ischemic vascular events |
| abstract | The invention relates to the pharmaceutical industry in general and in particular to the pharmaceutical industry involved in the production of medicaments for controlling systemic arterial hypertension and preventing ischemic vascular events. More specifically, the invention relates to a composition containing a calcium antagonist antihypertensive substance which is combined with a platelet aggregation inhibiting agent. The composition is characterised in that the aforementioned combination or association consists of a selected calcium channel antagonist substance known as Amlodipine besylate and a platelet aggregation inhibiting agent known as acetyl salicylic acid, in order to produce a product which has a synergistic effect for the treatment of systemic arterial hypertension and which prevents the risk of ischemic vascular events, with fewer side effects. |
| priorityDate | 2005-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 179.